Inovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright

HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a research report sent to investors on Tuesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on INO. Aegis restated a buy rating and issued a $14.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a hold rating to a buy rating and set a $8.75 price target for the company in a report on Tuesday, July 11th. Citigroup Inc. started coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They set a buy rating and a $10.00 target price for the company. BidaskClub cut Inovio Pharmaceuticals from a hold rating to a sell rating in a report on Friday, October 13th. Finally, Maxim Group reiterated a buy rating and set a $12.00 target price on shares of Inovio Pharmaceuticals in a report on Tuesday, September 12th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. Inovio Pharmaceuticals has an average rating of Hold and a consensus target price of $19.16.

Inovio Pharmaceuticals (INO) opened at 6.23 on Tuesday. Inovio Pharmaceuticals has a 52-week low of $5.28 and a 52-week high of $9.86. The firm’s market cap is $562.11 million. The firm has a 50-day moving average of $6.22 and a 200-day moving average of $6.64.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The company had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm’s revenue was up 229.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) EPS. Equities analysts anticipate that Inovio Pharmaceuticals will post ($0.95) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Inovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://baseballnewssource.com/markets/inovio-pharmaceuticals-inc-ino-pt-set-at-13-00-by-hc-wainwright/1720916.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Inovio Pharmaceuticals by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after acquiring an additional 129,164 shares in the last quarter. Wasatch Advisors Inc. lifted its position in Inovio Pharmaceuticals by 43.6% during the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after acquiring an additional 793,306 shares in the last quarter. Northern Trust Corp lifted its position in Inovio Pharmaceuticals by 2.8% during the 2nd quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after acquiring an additional 24,366 shares in the last quarter. Geode Capital Management LLC lifted its position in Inovio Pharmaceuticals by 12.5% during the 1st quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after acquiring an additional 62,045 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Inovio Pharmaceuticals by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after acquiring an additional 11,765 shares in the last quarter. 24.83% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1


Leave a Reply

 
© 2006-2017 BBNS.